This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2007 Sep;4(9):470-1.

doi: 10.1038/ncpuro0858. Epub 2007 Jul 10.

Molecular pathways and the hope of targeting angiogenesis

Cora N Sternberg¹

Affiliations

PMID: 17622236
DOI: 10.1038/ncpuro0858

Comment

Molecular pathways and the hope of targeting angiogenesis

Cora N Sternberg. Nat Clin Pract Urol. 2007 Sep.

. 2007 Sep;4(9):470-1.

doi: 10.1038/ncpuro0858. Epub 2007 Jul 10.

Author

Cora N Sternberg¹

Affiliation

¹ Department of Medical Oncology, San Camillo Forlanini Hospital, Nuovi Padiglioni, 4th floor Circonvallazione, Gianicolense 87, Rome, Italy. cstern@mclink.it

PMID: 17622236
DOI: 10.1038/ncpuro0858

No abstract available

PubMed Disclaimer

Comment on

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Motzer RJ, et al. N Engl J Med. 2007 Jan 11;356(2):115-24. doi: 10.1056/NEJMoa065044. N Engl J Med. 2007. PMID: 17215529 Clinical Trial.

Similar articles

Targeting neuropilin 1 as an antitumor strategy in lung cancer.
Hong TM, Chen YL, Wu YY, Yuan A, Chao YC, Chung YC, Wu MH, Yang SC, Pan SH, Shih JY, Chan WK, Yang PC. Hong TM, et al. Clin Cancer Res. 2007 Aug 15;13(16):4759-68. doi: 10.1158/1078-0432.CCR-07-0001. Clin Cancer Res. 2007. PMID: 17699853
Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
Cao Y. Cao Y. Adv Cancer Res. 2008;100:113-31. doi: 10.1016/S0065-230X(08)00004-3. Adv Cancer Res. 2008. PMID: 18620094 Review.
Angiogenesis and gliomas: current issues and development of surrogate markers.
Jouanneau E. Jouanneau E. Neurosurgery. 2008 Jan;62(1):31-50; discussion 50-2. doi: 10.1227/01.NEU.0000311060.65002.4E. Neurosurgery. 2008. PMID: 18300890 Review.
Targeting microRNA expression to regulate angiogenesis.
Kuehbacher A, Urbich C, Dimmeler S. Kuehbacher A, et al. Trends Pharmacol Sci. 2008 Jan;29(1):12-5. doi: 10.1016/j.tips.2007.10.014. Epub 2007 Dec 18. Trends Pharmacol Sci. 2008. PMID: 18068232
Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers.
Sabbah M, Emami S, Redeuilh G, Julien S, Prévost G, Zimber A, Ouelaa R, Bracke M, De Wever O, Gespach C. Sabbah M, et al. Drug Resist Updat. 2008 Aug-Oct;11(4-5):123-51. doi: 10.1016/j.drup.2008.07.001. Epub 2008 Aug 20. Drug Resist Updat. 2008. PMID: 18718806 Review.

See all similar articles

Cited by

Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage.
Stein WD, Yang J, Bates SE, Fojo T. Stein WD, et al. Oncologist. 2008 Oct;13(10):1055-62. doi: 10.1634/theoncologist.2008-0016. Epub 2008 Sep 30. Oncologist. 2008. PMID: 18827177 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.